Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company also develops Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other GI diseases, as well as nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALBO
Previous Symbol
CUSIPN/A
Phone857-254-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio19.43
Quick Ratio19.43
Price-To-Earnings
Trailing P/E Ratio-7.66
Forward P/E Ratio-6.52
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.01 per share
Price / Book4.01
Profitability
EPS (Most Recent Fiscal Year)($3.15)
Net Income$-24,410,000.00
Net MarginsN/A
Return on Equity-27.77%
Return on Assets-20.75%
Miscellaneous
Employees22
Outstanding Shares11,970,000
Market Cap$281.29 million
OptionableOptionable
Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions
What is Albireo Pharma's stock symbol?
Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How were Albireo Pharma's earnings last quarter?
Albireo Pharma Inc (NASDAQ:ALBO) posted its earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.97) by $0.20. The biopharmaceutical company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.55 million. View Albireo Pharma's Earnings History.
When is Albireo Pharma's next earnings date?
What price target have analysts set for ALBO?
4 Wall Street analysts have issued 12-month price objectives for Albireo Pharma's shares. Their predictions range from $50.00 to $69.00. On average, they expect Albireo Pharma's share price to reach $56.3333 in the next year. This suggests a possible upside of 133.5% from the stock's current price. View Analyst Price Targets for Albireo Pharma.
What is the consensus analysts' recommendation for Albireo Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.
What are Wall Street analysts saying about Albireo Pharma stock?
Here are some recent quotes from research analysts about Albireo Pharma stock:
- 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (11/15/2018)
- 2. Needham & Company LLC analysts commented, "Albireo provided a quarterly corporate update today and hosted an analyst/ investor event at the AASLD mtg yesterday. Mgmt reported progress w/ Phase 3 PEDFIC1 trial of IBAT inhibitor A4250 in PFIC1/2, announcing that 26 sites have now been opened. Top-line results are still expected around YE19. Recent presentations at NASPGHAN and AASLD mtgs provide additional context around PFIC natural history, unmet need, and A4250 therapeutic strategy. Mgmt continues to guide for another A4250 trial initiation in 2019, most likely Biliary Atresia or Alagille Syndrome. Reiterate BUY. Stock does not adequately reflect value of development efforts in pediatric liver disease." (11/13/2018)
Has Albireo Pharma been receiving favorable news coverage?
News headlines about ALBO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Albireo Pharma earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are some of Albireo Pharma's key competitors?
Some companies that are related to Albireo Pharma include Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Athenex (ATNX), ImmunoGen (IMGN) and Lexicon Pharmaceuticals (LXRX).
Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the folowing people:
- Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 55)
- Ms. Martha J. Carter, Chief Regulatory Officer (Age 66)
- Dr. Paresh N. Soni, Consultant (Age 58)
- Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
- Mr. Simon Harford, CFO & Treasurer
Who are Albireo Pharma's major shareholders?
Albireo Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.88%), FMR LLC (4.02%), Prosight Management LP (1.36%), Chicago Capital LLC (1.34%), Vanguard Group Inc (1.06%) and Dimensional Fund Advisors LP (0.69%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Life Sciences Maste Perceptive, Phase4 Partners Ltd, Plc Astrazeneca and Ronald Harold Wilfred Cooper. View Institutional Ownership Trends for Albireo Pharma.
Which institutional investors are selling Albireo Pharma stock?
ALBO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Virtus ETF Advisers LLC, TIAA CREF Investment Management LLC and Victory Capital Management Inc.. Company insiders that have sold Albireo Pharma company stock in the last year include Jan Mattsson and Phase4 Partners Ltd. View Insider Buying and Selling for Albireo Pharma.
Which institutional investors are buying Albireo Pharma stock?
ALBO stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Dimensional Fund Advisors LP, BlackRock Inc., Marshall Wace North America L.P., Chicago Capital LLC, Alps Advisors Inc., Acadian Asset Management LLC and Wells Fargo & Company MN. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.
How do I buy shares of Albireo Pharma?
Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albireo Pharma's stock price today?
One share of ALBO stock can currently be purchased for approximately $24.13.
How big of a company is Albireo Pharma?
Albireo Pharma has a market capitalization of $281.29 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo Pharma employs 22 workers across the globe.
What is Albireo Pharma's official website?
How can I contact Albireo Pharma?
Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]
MarketBeat Community Rating for Albireo Pharma (NASDAQ ALBO)
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
